Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells.
By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies.
Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Location: United States, California, Hayward
Employees: 11-50
Total raised: $666M
Founded date: 2019
Investors 6
Date | Name | Website |
- | Innovation... | innovation... |
- | Foresite C... | foresiteca... |
- | The Column... | thecolumng... |
- | Lux Capita... | luxcapital... |
- | TCG Crosso... | tcgcrossov... |
- | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 2
Date | Series | Amount | Investors |
07.01.2022 | Series B | $518M | - |
06.05.2021 | Series A | $148M | - |
Mentions in press and media 13
Date | Title | Description | Source |
02.06.2023 | Eikon Therapeutics Acquires Global Rights to Clinical-Stage ... | New assets establish foundation for Eikon’s expanding pipeline of in-house and acquired drug candida... | aithority.... |
01.06.2023 | Impact Therapeutics Entered into Global Partnership with Eik... | SHANGHAI and HAYWARD, Calif., June 1, 2023 /PRNewswire/ -- IMPACT Therapeutics ("Impact"),... | en.prnasia... |
07.01.2022 | US-based biopharmaceutical startup Eikon Therapeutics raises... | Eikon Therapeutics, Inc., a biopharmaceutical startup employing revolutionary technology at the inte... | vcbay.news... |
06.01.2022 | Early stage startups doubled their funding in 2021 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
06.01.2022 | Eikon Therapeutics Announces $517.8 Million Series B Raise | - | tcgcrossov... |
06.01.2022 | ‘How can you understand life if you don’t look at it live?’ ... | Adam Goulburn, a partner at Lux Capital, was first struck by Eikon Therapeutics’ pitch to use super ... | techcrunch... |
06.01.2022 | Early stage startups doubled their funding in 2021 | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
06.01.2022 | Eikon Therapeutics, Inc. announced that it has received $517... | On January 6, 2022, Eikon Therapeutics, Inc. closed the transaction. The company has received $517,7... | marketscre... |
06.01.2022 | Eikon Therapeutics Announces $517.8 Million Series B Raise a... | Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to d... | marketscre... |
06.05.2021 | Eikon Therapeutics lands $148M Series A | The Column Group has led a $148 million round for Eikon Therapeutics, the developer of a drug discov... | pitchbook.... |
Show more